Cost-effectiveness of mepolizumab vs anti-interleukin-5/5r biologic therapies for the treatment of adults with severe asthma with an eosinophilic phenotype: a Chilean healthcare system perspective.
- DOI
- 10.1080/13696998.2025.2520701
- Published
- 2025 Dec
- Container
- Journal of medical economics
- Publisher
- Not recorded
- Open access
- no
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1080/13696998.2025.2520701,
title = {Cost-effectiveness of mepolizumab vs anti-interleukin-5/5r biologic therapies for the treatment of adults with severe asthma with an eosinophilic phenotype: a Chilean healthcare system perspective.},
author = {Moraes Dos Santos F and Rodríguez Martínez C and Giovini V and Espinoza MA and Balmaceda C and Romero J},
year = {2025},
journal = {Journal of medical economics},
doi = {10.1080/13696998.2025.2520701},
url = {https://doi.org/10.1080/13696998.2025.2520701}
}RIS
TY - JOUR TI - Cost-effectiveness of mepolizumab vs anti-interleukin-5/5r biologic therapies for the treatment of adults with severe asthma with an eosinophilic phenotype: a Chilean healthcare system perspective. AU - Moraes Dos Santos F AU - Rodríguez Martínez C AU - Giovini V AU - Espinoza MA AU - Balmaceda C AU - Romero J PY - 2025 JO - Journal of medical economics DO - 10.1080/13696998.2025.2520701 UR - https://doi.org/10.1080/13696998.2025.2520701 ER -
APA
F, M. D. S., C, R. M., V, G., MA, E., C, B., & J, R. (2025). Cost-effectiveness of mepolizumab vs anti-interleukin-5/5r biologic therapies for the treatment of adults with severe asthma with an eosinophilic phenotype: a Chilean healthcare system perspective.. Journal of medical economics. https://doi.org/10.1080/13696998.2025.2520701
Source records
- pubmed · retrieved 2026-09-25T19:41:12.543Z
- europe-pmc · retrieved 2026-09-25T19:41:12.702Z